hepatitis

As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell -- in spite of Crucell's recent manufacturing troubles.

Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs -- the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of approximately $590 million in third quarter of 2010.

Its development of novel treatments for hepatitis C is leading Achillion to seek partnerships with major drugmakers. Many analysts see great potential for its drugs and expect it to strike one or more deals soon.

Do you have a tattoo? Have you ever wanted one? Having our bodies adorned with "skin art" is a very personal choice, and one which should not be taken lightly. I myself have a very nice tattoo on my upper left arm which features the heads of five of nature's big cats. It's a one-of-a-kind piece, it...